AQR Capital Management - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 199 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.

Quarter-by-quarter ownership
AQR Capital Management ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$520,500
+94.1%
73,517
+93.0%
0.00%0.0%
Q2 2023$268,140
-17.4%
38,088
-2.1%
0.00%0.0%
Q1 2023$324,493
+13.1%
38,908
+55.7%
0.00%0.0%
Q4 2022$286,908
+1.0%
24,992
+10.8%
0.00%0.0%
Q3 2022$284,000
-10.4%
22,560
-24.6%
0.00%0.0%
Q2 2022$317,000
-65.6%
29,917
-47.2%
0.00%
-50.0%
Q1 2022$922,000
-32.7%
56,679
-42.7%
0.00%0.0%
Q4 2021$1,369,000
-26.8%
98,864
-24.0%
0.00%
-33.3%
Q3 2021$1,869,000
+9.6%
130,073
+20.5%
0.00%0.0%
Q2 2021$1,706,000
+173.4%
107,921
+75.8%
0.00%
+200.0%
Q1 2021$624,000
+34.5%
61,386
-1.5%
0.00%0.0%
Q4 2020$464,000
+30.3%
62,346
-39.9%
0.00%0.0%
Q3 2020$356,000
-37.0%
103,777
-12.5%
0.00%0.0%
Q2 2020$565,000
+1245.2%
118,613
+468.4%
0.00%
Q1 2020$42,000
-74.4%
20,869
-56.2%
0.00%
Q4 2019$164,000
+118.7%
47,649
+81.5%
0.00%
Q3 2019$75,000
-54.3%
26,257
-39.3%
0.00%
Q2 2019$164,000
-57.1%
43,277
-7.7%
0.00%
Q1 2019$382,000
+5.8%
46,870
+4.9%
0.00%
Q4 2018$361,000
+159.7%
44,685
+53.9%
0.00%
Q1 2018$139,000
-46.7%
29,043
-45.3%
0.00%
Q4 2017$261,000
-24.6%
53,140
-19.6%
0.00%
Q3 2017$346,000
+14.6%
66,119
+21.7%
0.00%
Q2 2017$302,000
-14.0%
54,322
+30.1%
0.00%
Q1 2017$351,000
+26.3%
41,751
-57.3%
0.00%
Q2 2016$278,000
-21.2%
97,873
-21.5%
0.00%
-100.0%
Q1 2016$353,000
+39.0%
124,614
+407.3%
0.00%
Q4 2015$254,000
-58.6%
24,564
-54.4%
0.00%
-100.0%
Q3 2015$614,000
+86.6%
53,816
+144.0%
0.00%0.0%
Q2 2015$329,000
-84.1%
22,056
-90.4%
0.00%
-80.0%
Q1 2015$2,064,000
-64.3%
228,635
-51.9%
0.01%
-58.3%
Q4 2014$5,782,000
+72.3%
475,435
+38.6%
0.01%
+33.3%
Q3 2014$3,355,000
+133.1%
343,062
+204.0%
0.01%
+125.0%
Q2 2014$1,439,000
+21.7%
112,862
+1.0%
0.00%0.0%
Q1 2014$1,182,000
+63.3%
111,762
+17.3%
0.00%
+100.0%
Q4 2013$724,00095,2620.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q3 2021
NameSharesValueWeighting ↓
RP Management, LLC 3,846,154$27,230,77026.28%
Prosight Management, LP 2,408,135$17,049,5965.40%
Kynam Capital Management, LP 3,133,193$22,183,0063.63%
Saturn V Capital Management LP 982,458$6,955,8032.91%
AlphaCentric Advisors LLC 649,000$4,594,9202.61%
TANG CAPITAL MANAGEMENT LLC 1,800,000$12,744,0001.80%
SILVERARC CAPITAL MANAGEMENT, LLC 791,671$5,605,0311.70%
Eversept Partners, LP 2,479,103$17,552,0491.48%
DAFNA Capital Management LLC 652,000$4,616,1601.44%
Avoro Capital Advisors LLC 11,550,000$81,774,0001.28%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders